nPhase's AI clinical data platform promises smarter trial design, but before sponsors add another vendor, the activation-cycle math deserves...
Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors...
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at the operational...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring gaps nobody budgeted....
Merck and SCRI's Accelero™ collaboration targets community oncology enrollment, but the real test is whether 200+ sites can execute...
Curavit's acquisition of Lindus Health CRO assets combines 1,000+ global sites with DCT infrastructure—but site teams absorb the operational...
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-750x575.png)
59% of sites report recruitment blocked by process inefficiencies—the bottleneck isn't patient supply, it's the workflow that never gets...
Caidya and Simbec-Orion's merger creates a 6-month operational danger zone for sites running active studies. Here's what sponsor clinops...
Caidya and Simbec-Orion's June 2026 merger creates real site-level friction: dual CTMS logins, monitoring model gaps, and budget renegotiations...
